Drug Digest Video: Pairing the Right APIs and Excipients for Optimizing Formulations

Published on: 


Thursday January 27, 2022 at 11am EST | 10am CST | 8am PST In this new video series, Drug Digest, the Pharmaceutical Technology editors dive into APIs, excipients, and formulation advances, with a focus on pairing the right APIs and excipients for optimizing formulations and efficacy. Join the editors as they speak with experts from Bristol-Myers Squibb, BASF, Thermo Fisher Scientific, Wavelength Pharmaceuticals, and more to determine the most significant factors impacting API and excipient selection as well as the best modalities/drug product forms.

Register free: ​ https://www.pharmtech.com/pt_w/DD1

Event Overview:

Welcome to this episode of Drug Digest, a tech talk with the Pharmaceutical Technology editors, who discuss with experts the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products. In this episode, the editors dive into APIs, excipients, and formulation advances, specifically pairing the right APIs and excipients for optimizing formulations.

This episode of Drug Digest is sponsored by:

  • Veltek
  • Adare
  • Dyhydromatics
  • Coatings Place
  • Baxter

Interviews featuring:

  • Gregory Lane, PhD, Senior Research Investigator, Bristol-Myers Squibb
  • Nitin Swarnakar, Manager NA Applications Lab (Pharma Solutions), BASF
  • Ilan Avni, VP BD, Marketing and IP, Wavelength Pharmaceuticals
  • Matthias Bucerius, Head of Actives and Formulation, MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany
  • Anil Kane, PhD, Global Head of Technical and Scientific Affairs, Pharma Services, Thermo Fisher Scientific
  • Stephen Hoag, Professor at Dept. of Pharmaceutical Sciences, University of Maryland School of Pharmacy

Key Learning Objectives:

  • The factors impacting API and excipient selection, including how one company selects an excipient supplier
  • Determining the best modalities/drug product forms for certain APIs and excipients
  • New technologies, including 3D printing, SEED’s, and lymphatic delivery advantages/considerations
  • FDA pilot novel excipient program

Who Should Attend:

  • API, excipient and formulation CMOs, CDMOs, scientists, developers, and other technical experts
  • Drug analytics
  • Pharmaceutical companies looking to outsource work related to APIs and excipients
  • Packagers of small-molecule drug products
  • Companies offering formulation services


Dr. Gregory Lane
Senior Principal Investigator
Bristol-Myers Squibb

Greg Lane started working at Bristol-Myers Squibb (BMS) company in the year 2000 as a PhD organic chemist in the small-molecule API Process Technology department. During that time, he developed scalable syntheses and utilized process analytical technology (PAT) to monitor reactions and crystallizations from the laboratory to the pilot plant. In 2016, he moved to the Drug Product Science and Technology department at BMS, with a focus on oral solid dosage forms as well as biologics production. His initial efforts involved using Raman spectroscopy and other PAT tools to monitor and control upstream bioreactor production. This in turn led to requests to be able to monitor downstream unit operations, primarily with Fourier transform infrared (FT-IR) and UV-vis spectroscopy. As Greg likes to say: “Proteins are molecules too!”

Ilan Avni
VP BD, Marketing and IP
Wavelength Pharmaceuticals

Ilan Avni has more than 20 years of experience in the global pharma, API, and medical devices industries. Avni has been with Wavelength Pharmaceuticals since 2006 and served in various business development, pipeline, and portfolio management roles. Avni holds an MBA cum laude with a dual major in finance and marketing from Tel Aviv University and a BSc pharm cum laude from the Hebrew University of Jerusalem.

Matthias Bucerius
Head of Actives and Formulation

Matthais Bucerius serves as head of actives and formulation at MilliporeSigma, the US and Canadian life science business of Merck KGaA, Darmstadt, Germany. He joined the company in 2004 after working as a strategy consultant. While at Merck, he has held several positions, including head of global marketing and head of commercial Asia. He holds degrees in economics and a PhD in business administration.

Anil Kane, PhD
Global Head of Technical and Scientific Affairs, Pharma Services
Thermo Fisher Scientific

Anil Kane, PhD, has more than 25 years of experience in the science and business of taking molecules through the entire drug development process, spanning early-stage development to scale-up and commercial manufacturing and includes technical transfers between global sites and drug life cycle management.

Dr. Stephen Hoag
Professor at Dept. of Pharmaceutical Sciences
University of Maryland School of Pharmacy

Stephen W. Hoag, PhD, professor and director of the APhL, oversees project management, provides scientific oversight of projects, and handles client relations. In addition to his academic experience, he has worked for the World Health Organization, 3M Pharmaceuticals, and Abbott Laboratories. At all times, Dr. Hoag uses the extensive university knowledge base and resources to provide the most practical and affordable services to all clients.

Dr. Nitin Swarnakar
Manager NA Applications Lab (Pharma Solutions)

Nitin Swarnakar is a formulation scientist with over 14 years of combined (academic research/training/industrial) experience, and a very strong track record of publications primarily focused on various formulation aspects of small, peptide and protein molecules for oral and parenteral applications.

Register free: https://www.pharmtech.com/pt_w/DD1